AltruBio

CITELINE/In Vivo─Finding The Fire: AltruBio’s Novel Approach To Autoimmune Disease

Partnology─Biotech Leader Spotlight Series

Fierce Biotech─Executive Interview: Innovator(s) on Challenges in Advancing New Treatments for Late Phase and Launch

American Biomanufacturing Summit─Panel discussion: Advancing Digital Transformation and Manufacturing Excellence in Biomanufacturing

BioHub Podcast─How AltruBio is thriving in a tough market, and what’s ahead for the company in 2024

Scrip Asks─What Does 2025 Hold For Biopharma? Part 6: Therapeutic Area Advances

Needham─Private Company Spotlight: JPM 2025

Xtalks Life Science Podcast─Innovations in Immunomodulators for Diseases of the Immune System

Canaccord Genuity─A fireside chat with AltruBio, a cutting-edge company in the I&I space

BioXconomy─‘Luck only comes to the most prepared people,’ says AltruBio CEO

AltruBio Announces Formation of Scientific Advisory Board

AltruBio to Participate in the Upcoming Jefferies London Healthcare Conference and the Piper Sandler 36th Annual Healthcare Conference

Drug Target Review─Leveraging agonist antibodies to address immunological diseases

AltruBio Presents New In Vivo data for ALTB-268 at the 9th FIMSA 2024 Congress

Drug Discovery World (DDW)─North American biotech innovation: Who and where?

TVBS News─AltruBio CEO pushes for Taiwan’s role in drug development

San Francisco Business Times─Former Bayer, Genentech exec's biotech raises $225 million to target ulcerative colitis

AltruBio Secures up to $225M Oversubscribed Series B Financing to Advance the Clinical Development of Novel Immune Checkpoint Enhancer Program

BioSpace─AltruBio Raises $225M in Series B to Advance Ulcerative Colitis Candidate

FIERCE Biotech─AltruBio, after tweaking checkpoint drug, raises $225M for midphase ulcerative colitis program

Wall Street Jounal─AltruBio Gathers Funds as Biotechs Aim for Next Blockbuster Anti-Inflammatory Therapy

Endpoints News─In biotech's uneven recovery, 50 startups raised megarounds in first half of 2024

AltruBio to Participate in Upcoming May 2024 Medical Conferences

2023 ISPE annual meeting─Dr. Judy Chou Keynote Speech: The Pursuit of Excellence in Novel Therapeutic Development

Investor's Business Daily─Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space

AltruBio Announces Enrollment of First Patient in Phase 2 Clinical Program of ALTB-268 for the Treatment of Ulcerative Colitis

ISPE─ISPE Announces Leaders from Health Canada, AltruBio, AstraZeneca, Gilead, Lonza, Lyndra, and More to Speak at the 2023 ISPE Annual Meeting & Exp

AltruBio Announces FDA Clearance of IND Application for Immune Checkpoint Enhancer ALTB-268 to initiate a Phase 2 Clinical Trial for the Treatment of Ulcerative Colitis

STIFEL Financial Corp.─Virtual 2023 Stifel Immunology and Inflammation Summit

AltruBio Announces Positive Topline Data from Phase 1 Trial of Immune Checkpoint Enhancer ALTB-268 for the Treatment of Ulcerative Colitis

AltruBio to Present at the Federation of Clinical Immunology Societies (FOCIS) 2023 Annual Meeting

San Francisco Business Times─What’s one thing Bay Area needs for Biotech? CEOs let us know

AltruBio to Present at the 2023 BIO International Convention

Brilliance Within Coaching and Consulting─Breakthroughs and Belief: Life in BioTech – with Dr. Jesse Hall

AltruBio Announces Poster Presentation at Digestive Disease Week Conference 2023

Genetic Engineering & Biotechnology News─Making the Transition from Academia to CEO

AltruBio Announces Panels and Presentations at Three March Healthcare Conferences

San Francisco Business Times─Major Breakthroughs Achieved by Bay Area Women – Led Biotech Companies

AltruBio Announces First Participant Dosed in Phase 1 Trial of Next-Generation Immune Checkpoint Enhancer ALTB-268 for the Treatment of Ulcerative Colitis

Patient Worthy─AltruBio’s Dr. Jesse Hall Discusses Data on ALTB-168 for Acute GvHD

AltruBio Announces Poster Presentation on Immune Checkpoint Enhancer, ALTB-168 at Crohn’s & Colitis Congress 2023

Scrip Pharma Intelligence─What Does 2023 Hold For Biopharma? Part 2: M&A And Partnering

AltruBio to Present at Biotech Showcase™ 2023

AltruBio Presents New Positive Data from its Completed Phase 1b Study Evaluating ALTB-168 in Patients with Steroid-Refractory or Treatment-Refractory Acute Graft-Versus-Host-Disease at the 64th ASH Annual Meeting 2022

AltruBio Hosting Research & Development Update on Immune Checkpoint Enhancer Platform for T Cell Mediated Immunological Diseases

AltruBio Announces FDA Clearance of IND Application for ALTB-268, a Next-Generation Immune Checkpoint Enhancer for the Treatment of Ulcerative Colitis

Life Science Leader─Industry outlook 2023

Linkedin─Developing Novel Treatments for Immunological Disorders

AltruBio to Present at Stifel 2022 Healthcare Conference

AltruBio to Present New Phase 1b Data Evaluating Neihulizumab (ALTB-168) in Patients with Steroid-Refractory or Treatment-Refractory Acute Graft-Versus-Host-Disease at the 64th ASH Annual Meeting 2022

AltruBio President and CEO Judy Chou Appointed to the Governing Board of California’s Stem Cell & Gene Therapy Agency

Pharma’s almanac─What key indicators do you look at to predict the future of this industry

CIRM─Judy Chou, Ph.D., Appointed to Governing Board of California’s Stem Cell & Gene Therapy Agency

AltruBio President and CEO Judy Chou to Participate at the Longwood Healthcare Leaders Fall Webconference

BioSpace─AltruBio President and CEO Judy Chou to Participate at the Longwood Healthcare Leaders Fall Webconference

Labiotech.eu─ Top 10 biotech companies in Taiwan

Podcast─Identifying Targets on Problematic T Cells to Treat Immunological Diseases with Dr. Judy Chou AltruBio

Bioprocess Online─Overcoming Platform Inefficiencies In mAb Manufacturing

AltruBio to Present at the 2022 BIO International Convention

AltruBio Announces Completion of Enrollment in Phase 1 Clinical Study of Neihulizumab (ALTB-168) in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)

BioProcess International─Manufacturing must align with new modalities to drive efficiency, AltruBio

AltruBio to Present at BioProcess International US West 2022

BioSpace─Three Influential Women of Biopharma Breaking Down the Executive Barrier

Scrip Asks ─ What Does 2022 Hold For Biopharma? Part 4: Therapeutic Area Advances

AltruBio to Present at BIO CEO & Investor Conference

BioSpace ─ BioSpace Launches 2022 Hotbed Maps to Highlight Thriving Life Sciences Clusters

AltruBio to Present at Biotech Showcase™ 2022

BioSpace ─ Top Life Sciences Startups to Watch in 2022

Life Science Leader─What Trends Are 9 Biopharma CEOs Paying Attention To?

Podcast─CMC Developability Assessments For Rapid Ph.1 Entry With AltruBio's Gene Lee, Ph.D.

AltruBio to Present Abstract on Checkpoint Regulator Neihulizumab as a Novel Therapy for Immunological Diseases at the B&T Cell-Mediated Autoimmune Disease Drug Development Virtual Summit

BioPharm International─Trends in Outsourcing of Bioprocess Development

Bioprocess Online─mAb 2.0 For Psoriatic Arthritis

Podcast─From Bayer To Startup Bio With AltruBio's Dr. Judy Chou

Fierce Biotech─AltruBio snags a CMO after pivot from oncology to immunology

AltruBio Continues to Strengthen Management Team With the Appointment of Jesse Hall, M.D., as Chief Medical Officer

Life Science Leader─Companies To Watch: AltruBio

AltruBio Strengthens Management Team With Appointment of Jeroen Grasman as Chief Financial Officer

Fierce Biotech─New name, new board, new focus: AltruBio relaunches with $63M series A

ALTRUBIO RAISES $63 MILLION SERIES A ROUND TO CONTINUE ITS COMPANY TRANSFORMATION

Endpoints News─After a major facelift, AltruBio says it's ready for a pivotal fight against graft-versus-host disease

AltruBio’s Neihulizumab Granted Fast Track Designation by the FDA for Steroid Refractory Acute Graft Versus Host Disease

AltruBio to present at Biotech Showcase Digital 2021.

AltruBio Presented its Novel PSGL-1 Agonist Antibody Program for Immunological Diseases at FOCIS and Presented its Phase 2a Psoriatic Arthritis study results for lead molecule, Neihulizumab (AbGn-168H), at ACR.

AltruBio Announces First Patient Dosed in Phase 1b Study of Neihulizumab in Patients with Steroid-Refractory Acute Graft-versus-Host Disease.

AltruBio Inc. moves forward with clinical development of Neihulizumab in Steroid-Refractory Acute Graft-versus-Host Disease after encouraging Phase 1a results

AltruBio Inc. presented AbGn-107 Phase 1a chemo-refractory GI cancer results at ASCO-GI 2020

AltruBio’s presentation on Neihulizumab Phase 2a Ulcerative colitis results selected as Poster of Distinction at Digestive Disease Week (DDW) 2020

AbGenomics Holding Inc. Announces Company Name Change to AltruBio Inc.

The Business Journals─Bayer site head in Berkeley jumps to Peninsula cancer drug developer

Abgenomics welcomes Dr. Judy Chou as new President/CEO